CTLT News and Press, Catalent Inc. From 02/05/24

2024-02-05 12:38:30 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked Eli Lilly sees highest intraday trade since November...

2024-02-05 10:51:44 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked U.S. govt. opens bids in Medicare drug price negotia...

MONSEY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $63.50 per share in cash for which Catalent, Inc. (NYSE: CTLT) (“Catalent”) has agreed to be sold to Novo Holdings. Notably, Novo Holdings is t...

2024-02-05 08:31:42 ET Chenghe Acquisition  ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies  ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...

2024-02-05 06:39:48 ET More on Catalent Catalent: Debt Remains An Overhang Catalent spikes as CEO touts GLP-1 manufacturing capacity Baird upgrades Catalent to outperform, cites confidence in new CFO Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript ...

Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024 Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo H...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024...

New targets approved by Science Based Targets initiative (SBTi) Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced its targets to reduce greenhouse gas emissions (Scope 1 and 2) by 42% by 2030. The ...

2024-01-22 23:30:00 ET Summary During the first three quarters of 2023, Q4 earnings growth expectations remained stable. From an earnings growth contribution perspective, seven sectors have positive earnings contributions while four sectors have negative earnings contributions. ...

2024-01-16 11:49:56 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value Citi’s 30 stocks for its 2024 top themes Top overweight stocks with high growth and low volume - MS Seeking Alpha’s Quant Rating...